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The glycosyl donor, polyprenyl monophosphoman-
nose (PPM), has been shown to be involved in the bio-
synthesis of the mycobacterial lipoglycans: lipomannan
and lipoarabinomannan. The mycobacterial PPM syn-
thase (Mt-ppm1) catalyzes the transfer of mannose from
GDP-mannose to polyprenyl phosphates. Based on se-
quence homology to Mt-ppm1, we have identified the
PPM synthase from Corynebacterium glutamicum. In
the present study, we demonstrate that the corynebac-
terial synthase is composed of two distinct domains; a
catalytic domain (Cg-ppm1) and a membrane domain
(Cg-ppm2). Through the inactivation of Cg-ppm1, we ob-
served a complex phenotype that included altered cell
growth rate and inability to synthesize PPM molecules
and lipoglycans. When Cg-ppm2 was deleted, no observ-
able phenotype was noted, indicating the clear organi-
zation of the two domains. The complementation of the
inactivated Cg-ppm1 strain with the corresponding my-
cobacterial enzyme (Mt-Ppm1/D2) led to the restoration
of a wild type phenotype. The present study illustrates,
for the first time, the generation of a lipoglycan-less
mutant based on a molecular strategy in a member of
the Corynebacterianeae family. Lipoglycans are impor-
tant immunomodulatory molecules involved in deter-
mining the outcome of infection, and so the generation
of defined mutants and their subsequent immunological
characterization is timely.
Corynebacterial strains are widely distributed throughout
nature and represent an important branch of the Actinomyce-
tales family. The human pathogen Corynebacterium diphthe-
riae is the causal agent of diphtheria, and serious economic
losses occur from the infection of animals by corynebacterial
strains, such as Corynebacterium pseudotuberculosis and
Corynebacterium matruchotti (2, 3). In addition, Corynebacte-
rium glutamicum is of industrial importance producing large
quantities of amino acids worldwide (4). Corynebacteria belong
to a suprageneric actinomycete taxon termed the Corynebacte-
rianeae (5), which includes mycobacteria, rhodococci, nocar-
diae, and other closely related genera. Therefore, it is of no
surprise to find that corynebacteria and mycobacteria share a
similar cell envelope ultrastructure, which comprises a core
mycolyl-arabinogalactan peptidoglycan complex, termed
mAGP (6, 7).
An important class of components, found within the cell
envelope, are the biosynthetically related glycolipids, phos-
phatidyl-myo-inositol mannosides (PIMs),1,2 and lipoglycans,
termed lipomannan (LM) and lipoarabinomannan (LAM).
These glycolipids and lipoglycans are present within the cell
envelope of both mycobacteria (8) and corynebacteria (7, 9). The
basic structural features of mycobacterial LAM are well de-
scribed elsewhere and reveal that LAM possess an am-
phipathic tripartite structure (10–13). The two common do-
mains include a mannosyl-phosphatidyl-myo-inositol anchor
(MPI), with a polysaccharide backbone consisting of mannose
and arabinose that are further elaborated by either mannooli-
gosaccharide or phosphoinositol caps, representing the third
domain, and resulting in LAM being termed ManLAM (14, 15)
or PILAM (16, 17), respectively. In addition, a new class of
LAM, isolated and characterized from Mycobacterium chelo-
nae, has been shown to be devoid of any capping motifs, and is
termed AraLAM (18).
Both ManLAM and PILAM exhibit a broad range of immu-
nomodulatory activities. For example, ManLAM inhibits a
number of the immune system effector functions, including
interferon--mediated activation of macrophages (19–21).
Moreover, ManLAM can inhibit the production of pro-inflam-
matory cytokines, interleukin-12 (22) and tumor necrosis fac-
tor- (23). Thus, it appears that slow growing mycobacteria
possess a virulence factor enabling their persistence within the
host. Conversely, PILAM can induce a pro-inflammatory re-
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sponse in a Toll-like 2 receptor (TLR-2) dependent manner (24),
and as a consequence PILAM are likely to favor the killing of
fast growing mycobacteria. The biological importance of the
capping motifs found in ManLAM is now without doubt, rein-
forcing an emerging paradigm that “capped” LAM molecules
possess immunomodulatory type properties (22, 25, 26).
A number of non-mycobacterial actinomycetes possess lipo-
glycans, including Rhodococcus ruber (27), Rhodococcus equi
(28), Amycolatopsis sulfurea (29), and Tsukamurella pauro-
metabola.3 Structurally, these lipoglycans are related to myco-
bacterial LAM, but are typically smaller in size. Nevertheless,
they possess a similar global architecture, with the most sig-
nificant difference related to the degree of arabinosylation and
mannosylation. Thus, it would seem that these close relatives
have evolved a specific set(s) of enzymes dedicated to the pro-
duction of these biosynthetically related PIMs, LM and LAM.
As a result, a plethora of information exists to study lipoglycan
biosynthesis within the Actinomycetales family, through the
use of genomic and metabolomic approaches, linked to the use
of more genetically tractable species, such as the industrial
important bacilli, C. glutamicum.
Although the structure of mycobacterial LAM has been well
documented (10–13), the genetics of its biosynthesis still re-
main largely ill defined. It involves the addition of Manp resi-
dues to phosphatidyl-myo-inositol (PI) to produce both the
short PIMs (2–6 Manp residues) and LM, which is further
glycosylated with arabinan to form LAM. The biosynthetic
relationship of PI 3 PIMs 3 LM 3 LAM has recently been
supported by biochemical (30, 31) and genetic studies (32–34).
Besra et al. (31) demonstrated that Ac1PIM2 (according to the
nomenclature of Kordulakova et al. (Ref. 1)) is specifically
extended by the addition of Manp residues from the alkali-
stable sugar donor polyprenyl monophosphomannose (PPM) to
form higher PIMs and “linear” LM. The generation of PPM,
which results from the transfer of Manp from GDP-Manp to a
polyprenyl phosphate, has been studied in M. tuberculosis
H37Rv, and is catalyzed by a PPM synthase, now termed
Mt-ppm1 (Rv2051c) (35).
In the present study we have established that C. glutamicum
possess both PIMs and lipoglycans, which are reminiscent of
M. tuberculosis products, suggesting conserved biosynthetic
machineries within the two bacilli. Furthermore, through com-
parative genomic analyses, we have identified the corynebac-
terial PPM synthase Cg-ppm1, analogous to Mt-ppm1/D2. The
disruption of Cg-ppm1 through homologous recombination led
to a lipoglycan-less phenotype. In addition, complementation
with Mt-ppm1/D2 led to restoration of lipoglycan biosynthesis
in C. glutamicum. These results demonstrate the first biochem-
ical and molecular description of lipoglycan biosynthesis in a
non-mycobacterial species and highlight the inherent useful-
ness of examining related species to probe complex biosynthetic
pathways.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions—Escherichia coli
DH5mcr and C. glutamicum ATCC 13032 (the wild type strain, and
referred to for the remainder of the text as C. glutamicum) were grown
in Luria-Bertani (LB) broth (Difco) at 37 and 30 °C, respectively. The
mutants generated by this study were grown on complex medium LB-
HIS (which contained per liter: 5 g of tryptone, 5 g of NaCl, 2.5 g of yeast
extract, 18.5 g of brain heart infusion (Difco Labs Ltd, Surrey, UK), and
90.1 g of sorbitol). Antibiotics were used at the following concentrations:
50 g/ml kanamycin, 10 g/ml chloramphenicol, and 10 g/ml tetracy-
cline. Growth curves were performed using the minimal medium CGXII
(36), except that 30 mg/liter protocatechuic acid was included as a
chelating agent. Mutants were grown overnight on LBHIS, harvested,
washed once with 0.9% NaCl, and inoculated into CGXII to give a
starting optical density of 1, harvested again, washed once with 0.9%
NaCl, and lyophilized. For lipid and lipoglycan analyses, along with
crude cellular extract preparations, cells were grown in an identical
manner. For the preparation of membranes, bacterial strains were
grown in LB broth, supplemented with antibiotics, grown to mid log
phase, harvested by centrifugation, washed with PBS (50 mM, pH 7.5),
and stored at 20 °C until further use.
Plasmids and DNA Manipulation—To enable inactivation of Cg-
ppm1 in the chromosome of C. glutamicum, the plasmid pK18mob-Cg-
ppm1-int was generated. An internal fragment of Cg-ppm1 was ampli-
fied via PCR using primers 5-CCCTGCGGTCATATCGGTCA-3 and
5-GCGTACATGGCTGGCTTCCA-3. The resulting fragment was pu-
rified via gel electrophoresis and ligated with SmaI-cleaved pK18mob
(37), using the SureClone ligation kit (Amersham Biosciences, Uppsala,
Sweden).
Overexpression of Mt-ppm1/D2 was obtained with pXMJ19-Mt-
ppm1/D2. The primers used were 5-GCTCTAGAAAGGAGATATAGA-
TATGACCACCGGCCAGCC-3 and 5-CGGAATTCTTATTCGGTCAC-
GTCGGCGC-3 (with the cloning sites in bold and the ribosome binding
site and start codon, introduced to enable expression of domain D2 of
Mt-ppm1, underlined). The amplified fragment was purified, treated
with XbaI and EcoRI, and ligated with similarly treated pXMJ19 (38) to
give pXMJ19-Mt-ppm1/D2.
Overexpression of Cg-ppm1 was obtained with pVWEx2-Cg-ppm1.
The primers used were 5-GCTCTAGAAAGGAGATATAGATATGAGC-
AGTGAGGCAGTAGAT-3 and 5-CGGGATCCTTAGAGCCAGGTGTT-
GCGC-3. The fragment was cloned with the SureClone ligation kit in
pUC18, excised as an XbaI/BamHI fragment from the resulting vector,
and ligated with similarly treated pVWEx2.
The in-frame deletion of Cg-ppm2 in C. glutamicum was achieved
with pK19mobsacB-Cg-ppm2. This plasmid was made using cross-over
PCR (39) to enable the one-ligation step integration of upstream to-
gether with downstream sequences of Cg-ppm2 into pK19mobsacB (37).
Using the Expand Highfidelity PCR system (Roche, Basel, Switzerland)
in the first PCR round, two separate amplification products were
generated with 5-CGCGGATCCGAGCGCGACGCTGATGTAGAC-3
(Cg-ppm2-3-out)/5-ACAAATTCAAATCACCTACCCGCGAAAAAGG-
CAGCAACTAATCG-3 (Cg-ppm2-3-in) and with 5-CGCGATCCGCG-
GGCCAAGCGCATGCGCAGTG-3 (Cg-ppm2-5-out)/5-GGGTAGGTG-
ATTTGAATTTGTAGTTGGGCCCGTGGACATCT-3 (Cg-ppm2-5-in).
Both PCR products were purified and used as a template to amplify,
with primers Cg-ppm2-5-out and Cg-ppm2-3-out, a fragment devoid of
Cg-ppm2 that was treated with BamHI and ligated with BamHI-
cleaved pK19mobsacB to give pK19mobsacB-Cg-ppm2. The inserts in
all final constructs were confirmed by sequencing.
Construction of Strains—Plasmids were usually introduced via elec-
troporation, but conjugation was used when electroporation failed. Con-
jugation was done with E. coli S-17-1 as the donor, and its sensitivity to
nalidixic acid (50 g/ml) was used after plating for counterselecting.
Selection of recombinant C. glutamicum strains for the presence of the
replicative plasmid pVWEx2-Cg-ppm1 used 2 g/ml tetracycline, and
pXMJ19-Mt-ppm1/D2 used 5 g/ml chloramphenicol. The ppm1 gene
was inactivated in C. glutamicum by transformation with pK18mob-
Cg-ppm1-int. A recombinant strain was selected with 15 g/ml kana-
mycin and the chromosomal inactivation confirmed by PCR. The result-
ing strain was termed C. glutamicum::ppm1.
To achieve deletion of Cg-ppm2, plasmid pK19mobsacB-Cg-ppm2
was introduced into C. glutamicum by conjugation. Selection for resist-
ance to kanamycin yielded two clones, indicating integration of the
vector in the chromosome by homologous recombination. Each of the
clones was subjected to the subsequent selection for the second homol-
ogous recombination event. In this round the presence of sacB (together
with addition of 10% sucrose to the medium) resulted in a positive
selection of clones where vector sequences were lost again (37). The
correct integration of sequences into the chromosome and absence of
sequences, respectively, in the resulting strain, C. glutamicumppm2,
was verified by PCR using two different primer pairs.
Extraction of Whole Cell Lipids—Lyophilized C. glutamicum, C. glu-
tamicum::ppm1, and C. glutamicum::ppm1 pMt-ppm1/D2 were ex-
tracted by three consecutive overnight extractions in CHCl3/CH3OH
(2:1, v/v). These lipidic extracts were combined, dried under reduced
pressure, Folch-washed, CHCl3/CH3OH/H2O (4:2:1, v/v/v), and again
dried under reduced pressure and analyzed by MALDI-MS.
Extraction of Lipoglycans—500 mg of lyophilized cells of C. glutami-
cum, C. glutamicum::ppm1, and C. glutamicum::ppm1 pMt-ppm1/D2
were delipidated as described above. The delipidated cells were then
resuspended in 10 ml of PBS (50 mM, pH 7.5) and 10 ml of phenol-3 K. J. C. Gibson and G. S. Besra, unpublished results.
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saturated PBS and incubated with stirring at 90 °C for 60 min (40, 41).
The mixture was then centrifuged at 4500  g for 10 min and the upper
aqueous phase removed and dialyzed for 24 h against water, with
frequent changes. The recovered samples, containing lipoglycans and
glycans, were dried under reduced pressure and resuspended in 500 l
of 15% propan-1-ol in 50 mM ammonium acetate buffer and loaded onto
an octyl-Sepharose CL-4B column (Sigma UK, 30  1.5 cm) and eluted
with 3 column volumes of the same buffer at 5 ml/h, enabling the
removal of non-lipidic moieties (22). The retained lipoglycans were
eluted with 3 column volumes of 50% propan-1-ol in 50 mM ammonium
acetate buffer. The resulting lipoglycans were either analyzed by SDS-
PAGE, followed by periodic acid-silver nitrate staining, or subjected to
further purification using gel filtration chromatography, as described
by Gibson et al. (29), for glycosidic linkage analysis.
Glycosidic Linkage Analysis—Glycosyl linkage composition was per-
formed according to the modified procedure from Ciucanu and Kerek
(42). The per-O-methylated lipoglycans were hydrolyzed using 500 l of
2 M trifluoroacetic acid at 110 °C for 2 h, reduced using 350 l of a 10
mg/ml solution of NaBD4 (1 M ammonium hydroxide/ethanol; 1:1, v/v)
and per-O-acetylated using 300 l of acetic anhydride for 1 h at 110 °C.
The resulting alditol acetates were solubilized in cyclohexane before
analysis by gas chromatography and gas chromatography coupled to
mass spectrometry.
Preparation of Enzyme Fractions—C. glutamicum, C. gluta-
micum::ppm1, and C. glutamicum::ppm1 pMt-ppm1/D2 were grown (10
g wet weight), washed, and re-suspended in 30 ml of buffer A, which
contained 50 mM MOPS (adjusted to pH 8.0 with KOH), 5 mM -mer-
captoethanol, and 10 mM MgCl2, at 4 °C and subjected to sonication
(Soniprep 150, MSE Sanyo Gallenkamp, Crawley, Sussex, UK; 1-cm
probe) for a total of 10 cycles in 60-s pulses and 90-s cooling intervals.
The sonicates were centrifuged at 27,000  g for 60 min at 4 °C.
Membrane fractions from the three strains were obtained by further
centrifugation of the supernatant at 100,000 g for 90 min at 4 °C. The
supernatant was carefully removed and the membranes gently re-
suspended in buffer A. Protein concentrations were determined using
the BCA Protein Assay Reagent kit (Pierce Europe, Oud-Beijerland,
Netherlands).
Mannosyltransferase Assays—Membrane fractions from C. glutami-
cum were assayed and compared with C. glutamicum::ppm1 and
C. glutamicum::ppm1 pMt-ppm1/D2 for in vitro mannosyltransferase
activity, using methods adapted from Besra et al. (31). Reaction mix-
tures contained 95 g of membranes (total protein), buffer A, 0.1 mM
dithiothreitol, and 10 mM CaCl2 either with or without 5 g of ampho-
mycin (a lipopeptide antibiotic that specifically inhibits polyprenyl-P-
requiring synthases and the subsequent synthesis of polyprenol-P-Man)
in a total volume of 50 l. Reactions were incubated for 10 min at 37 °C
prior to the addition of 0.25 Ci of GDP-[14C]Man (Amersham Bio-
sciences; 303 mCi/mmol) and held at 37 °C for an additional 30 min. The
reactions were stopped by the addition of 4 ml of CHCl3/CH3OH/H2O
(10:10:3, v/v/v) and incubated at room temperature for 30 min, followed
by the addition of 1.75 ml of CHCl3 and 0.75 ml of H2O. The lower
organic layer of the biphasic mixture was washed three times with 2 ml
of CHCl3/CH3OH/H2O (3:47:48, v/v/v), dried under a stream of nitrogen,
and resuspended in 200 l of CHCl3/CH2OH (2:1, v/v). The transfer of
[14C]Man from GDP-[14C]Man to the in vitro synthesized PI/PIMs was
quantified by scintillation counting using 5 ml of EcolumeTM (ICN
Biomedicals, Costa Mesa, CA) and the materials analyzed by thin layer
chromatography (TLC)/autoradiography as described previously (34).
Analysis of Reaction Products—Large scale reaction mixtures con-
taining unlabeled GDP-Man (80 mM) and the other components were
prepared and processed as described above. The reaction products were
dried, applied to preparative TLC plates (plastic-backed plates of Silica
gel 60 F254; E. Merck, Darmstadt, Germany) along with radiolabeled
material (50,000 cpm) to trace the cold enzymatically synthesized prod-
ucts and developed in CHCl3/CH3OH/NH4OH/H2O (65:25:0.5:3.6,
v/v/v/v). Autoradiography was performed as described previously (34).
The band corresponding to the new enzymatically synthesized PIM
product was recovered from plates using 4 ml of CHCl3/CH3OH/H2O
(10:10:3, v/v/v) at room temperature for 30 min followed by the addition
of 1.75 ml of CHCl3 and 0.75 ml of H2O. The lower organic layer of the
biphasic mixture was washed three times with 2 ml of CHCl3/CH3OH/
H2O (3:47:48, v/v/v), dried under a stream of nitrogen, and analyzed
using MALDI-MS, as described previously (33).
Polyprenol Monophosphomannose Synthase Assays—Reaction mix-
tures assessing [14C]Man incorporation consisted of 0.25 Ci of GDP-
[14C]Man (Amersham Biosciences; 303 mCi/mmol), 62.5 M ATP, 10 M
MgCl2, and 90 g of membrane preparations, prepared as described
previously, in a final volume of 50 l (35). In some cases, exogenous lipid
monophosphate substrates (C35, heptaprenyl monophosphate; C40, oc-
taprenyl monophosphate; C50, decaprenyl monophosphate; C55, unde-
caprenyl monophosphate; and C60, dodecaprenyl monophosphate) were
added to reaction mixtures at a final concentration of 0.25 mM in 0.25%
CHAPS. The reaction mixtures were then incubated at 37 °C for 30 min.
Extraction and Characterization of [14C]Mannose-labeled Products
from PPM Reaction—The above enzymatic reactions were terminated
by the addition of 4 ml of CHCl3/CH3OH/0.8 M NaOH (10:10:3, v/v/v)
followed by further incubation at 50 °C for 20 min. The mixtures were
then allowed to cool to room temperature, and 1.75 ml of CHCl3 and
0.75 ml of H2O were added. The mixture was vortexed and centrifuged,
and the upper aqueous phase discarded. The organic phase was washed
three times with 2 ml of CHCl3/CH3OH/H2O (3:47:48, v/v/v), dried
under a stream of nitrogen to yield an organic fraction, which contained
exclusively the mild-alkali stable family of PPMs. The resulting PPMs
were resuspended in 200 l of CHCl3/CH3OH (2:1, v/v), and aliquots (20
l) were dried under a stream of nitrogen in a scintillation vial prior to
scintillation counting using 5 ml of EcolumeTM (ICN Biomedicals). Thin
layer chromatography of the reaction mixtures, usually aliquots repre-
senting 10% of the reaction mixtures, was conducted on aluminum-
backed plates of Silica gel 60 F254 (E. Merck, Darmstadt, Germany)
using CHCl3/CH3OH/NH4OH/H2O (65:25:0.4:3.6, v/v/v/v). Autoradio-
grams were obtained as described previously (34).
RESULTS
Genome Comparison of the ppm Locus—Previous work has
identified that there are subtle variations in the organization of
the ppm1 locus in mycobacterial strains (35). The well charac-
terized Mt-ppm1 gene of M. tuberculosis is a large polypeptide
consisting of two domains, Mt-ppm1/D1 (functional domain)
and Mt-ppm1/D2 (catalytic domain), shown in Fig. 1A. How-
ever, a great deal of heterogeneity pertaining to this gene is
evident within several mycobacterial species. For instance, in
Mycobacterium smegmatis these domains are encoded by two
separate genes, encoding Ms-ppm1 and Ms-ppm2 (Fig. 1A),
which have recently been shown to interact with each other in
vivo as revealed by a bacterial two-hybrid system (43).
To gain information on the presence and organization of
orthologous genes in related bacteria like C. glutamicum, and
to analyze for the existence of paralogues, the Mt-ppm1/D1 and
Mt-ppm1/D2 domains were blasted individually against the
genomes of selected Corynebacterianeae in the hope of under-
standing the genetic organization of these genes within other
members of this family. A phylogenetic tree constructed for the
closest homologues of Mt-ppm1/D1 is shown in Fig. 1B. Inter-
estingly, a very similar tree was obtained for the polypeptides
that are orthologous to Mt-ppm1/D2, suggesting their common
evolution together with D1 polypeptides (Fig. 1C). Indeed, with
further comparison of the 16 S ribosomal RNA tree (Fig. 1D),
there is evidence that both D1 and D2 polypeptides were al-
ready present before species separation occurred within the
Corynebacterianeae, and that they were retained during ver-
tical descent. When this evidence is taken together, one may
conclude that these polypeptides catalyze core functions within
this suborder of the Actinomycetales. In addition, the presence
of an additional D2 paralogue in C. glutamicum (Fig. 1C) is
apparently a more recent evolutionary event, because a phage
integrase site is directly adjacent to the corresponding gene;
moreover, this is absent in the closest related species, Coryne-
bacterium efficiens (Fig. 1D).
Through further analysis of the M. tuberculosis and M. av-
ium genomes, we identified the presence of two sequences that
are distantly related to Mt-ppm1/D2 (not shown in Fig. 1C).
Interestingly, a gene that is of similar size to Mt-ppm1/D1
directly precedes these sequences; furthermore, these preced-
ing genes also encode a protein with transmembrane domains.
One may assume that, with this level of genetic organization,
these paralogues are organized within an operon, and might
constitute a functional complex similar to Mt-ppm1. Indeed, it
would appear that both D1 and D2 domains are general struc-
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tural elements that occur more frequently in mycobacteria
than in corynebacteria.
In all Corynebacterial species examined to date, both ppm
domains are encoded by non-overlapping genes, which is also
the case in M. smegmatis and Mycobacterium marinum, with
the largest gap of 32 bp present in C. glutamicum. In contrast,
members of the M. tuberculosis complex (H37Rv, CDC1551,
Mycobacterium bovis) exhibit a different level of genetic orga-
nization, whereby both domains are fused to generate one
multifunctional polypeptide (Fig. 1A). This difference may in-
dicate a more recent episode of protein evolution, which is in
accord with the notion that this branch of slow growing myco-
bacteria represents the most recently evolved subset of the
genus (44).
Construction of C. glutamicum ppm Mutants—The gene do-
mains identified as orthologous to Mt-ppm1 in C. glutamicum
were preliminarily termed Cg-ppm1 and Cg-ppm2, catalytic
domain and putative transmembrane domain, respectively, ac-
cording to the known function of ppm1 in M. tuberculosis (35)
and consistent with the sequence and conserved genome struc-
ture of both organisms.
To inactivate Cg-ppm1, the non-replicative plasmid pK18-
mob-Cg-ppm1-int was used to transform the C. glutamicum
wild type to kanamycin resistance (Fig. 2A). Six colonies were
obtained, all exhibiting smaller colony sizes than the wild type,
approximately 0.5 and 2 mm, respectively, when grown at
30 °C for 2 days on LB media. One of the recombinant clones
was analyzed in detail via PCR. For this purpose two different
primer pairs were used, each pair hybridizing with vector and
Cg-ppm1 sequences. In both cases the expected fragment was
obtained, confirming the integration of the vector into the tar-
get gene (Fig. 2, A and C). The disruption mutant obtained was
termed C. glutamicum::ppm1. In addition, a strain with an
in-frame deletion of Cg-ppm2, termed C. glutamicumppm2,
was generated (shown in Fig. 2, B and C), and included in
growth studies.
Growth of C. glutamicum Mutants—To assay for any poten-
tial in vivo function of Cg-Ppm1 and Cg-Ppm2, growth rates of
the generated mutants and controls were analyzed in liquid
culture using salt medium. As seen in Fig. 3, the growth rate of
C. glutamicum::ppm1 was impaired. Indeed, the growth rate of
the mutant was 0.25 h1 as compared with 0.34 h1, obtained
for the wild type. The optical density of C. glutamicum::ppm1
only became comparable with that of the wild type after 25 h of
growth. As expected, when pVWEx2-Cg-ppm1 was introduced
into C. glutamicum::ppm1, with the resulting strain referred to
as C. glutamicum::ppm1 pCg-ppm1, growth was restored to a
rate equivalent to wild type (Fig. 3). This result indicates that
Cg-ppm1 is not an essential gene for growth, although it is
required for optimal growth rate. Electron microscopic analy-
ses of the mutated cells did not reveal any ultrastructural
changes when compared with the wild type (data not shown).
Intriguingly, when the growth rate of the strain C. glu-
tamicumppm2 was assayed, which does not possess the pro-
tein domain corresponding to Mt-Ppm1/D1, no effect on growth
rate was observed (Fig. 3). This has been assigned as a putative
transmembrane domain that is thought to play a role in stabi-
lizing the catalytic domain (Cg-Ppm1, or Mt-Ppm1/D2) (35, 43).
With this result one can draw two conclusions: that the exact in
vivo roles of Cg-Ppm2, or Mt-Ppm1/D1 are not completely un-
derstood, or that, if required, Cg-Ppm1 or Mt-Ppm1/D2 may be
able to self-stabilize in close proximity to the membrane, as
suggested previously.
In C. glutamicum a paralogue of Cg-ppm1 is present, which
is of similar length (250 instead of 270 amino acids) and shares
76% identity with the gene product of Cg-ppm1. Nevertheless,
when the plasmid-encoded paralogue was introduced to
C. glutamicum::ppm1, no restoration of growth rate was ob-
served (data not shown), which might indicate, together with
the apparent recent origin, that this gene is a non-functional
copy.
Expression of Mt-ppm1/D2 and Functional Complementation
of C. glutamicum::ppm1—Plasmid pXMJ19-Mt-ppm1/D2 was
constructed to contain domain 2 of the M. tuberculosis ppm1
gene, extending from amino acid residue 594 to residue 874. In
the plasmid a start codon and an appropriate ribosome-binding
site were introduced. In this study the plasmid was used to
transform C. glutamicum::ppm1 to give C. glutamicum::ppm1
pXMJ19Mt-ppm1/D2, with the resulting strain referred to as
C. glutamicum::ppm1 pMt-ppm1/D2. When a crude cellular
extract of this complemented strain was analyzed by SDS-
PAGE, an extra protein band was observed that was absent in
the uncomplemented mutated strain (Fig. 4, lanes 3 and 2,
respectively). MALDI-MS analyses identified tryptic digests of
the Mt-Ppm1/D2 fragments with a coverage 40% (data not
shown). Therefore, domain 2 of the mycobacterial polyprenyl
monophosphomannose synthase is able to form a stable protein
in C. glutamicum::ppm1, an expected result that confirms the
FIG. 1. The ppm locus in the Corynebacterianeae and the re-
latedness of the separate encoded domains. A, an overview of the
genetic organization is shown with both genes either fused (top), over-
lapping (middle), or separated (bottom). A fusion is present in M. tu-
berculosis H37Rv (Mt-ppm1) and further members of this complex
including M. bovis (Mb-ppm1). The genes are overlapping in the case of
M. avium (Ma-ppm2, Ma-ppm1) and M. leprae (Ml-ppm2, Ml-ppm1).
The genes are separated in the case of M. smegmatis (Ms-ppm2, Ms-
ppm1), M. marinum (Mm-ppm2, Mm-ppm1), C. diphtheriae (Cd-ppm2,
Cd-ppm1), C. efficiens (Ce-ppm2, Ce-ppm1), and C. glutamicum (Cg-
ppm2, Cg-ppm1). B, an unrooted phylogenetic tree of the D1 domains is
shown, and in C a similar tree for the D2 domains. D, the phylogenetic
tree is shown comparing the Corynebacterianeae under study, as de-
rived from the 16 S ribosomal RNA sequences.
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clear domain and genetic organization of the homologous pro-
teins (Fig. 1A).
The growth of the complemented strain (C. glutamic-
cum::ppm1 pMt-ppm1/D2) was analyzed as above in salt me-
dium. When the inactivated mutant was complemented with
the plasmid containing Mt-ppm1/D2, recovery of growth was
observed, illustrated in Fig. 3. In summary, Mt-Ppm1/D2 is
able to replace the activity of the corresponding Cg-ppm1, and
the identified polyprenyl monophosphomannose synthase ac-
tivities (35) are in part the result of this protein. This confirmed
that the Mt-Ppm1/D2 domain itself is functional, and sufficient
to restore growth rate.
Incorporation of GDP-[14C]Mannose by Enzymatic Extracts
from C. glutamicum, C. glutamicum::ppm1, and C. glutami-
cum::ppm1 pMt-ppm1/D2—To further prove that the altered
growth rates observed for C. glutamicum::ppm1 were the result
of this strain lacking a functional copy of a PPM synthase, we
examined membrane extracts prepared from C. glutamicum,
C. glutamicum::ppm1, and C. glutamicum::ppm1 pMt-ppm1/
D2, and compared their relative PPM synthase activities.
Examination of the corynebacterial PPM family by TLC/
autoradiography indicated that C. glutamicum possess one
species of PPM (Fig. 5). To identify the species present in
chromosomal organization of ppm1 are indicated as arrows marked
F1/R1, F1/P1, and P2/R1. B, strategy to delete the entire structural
gene of ppm2 using vector pK19mobsacB-Cg-ppm2. This vector carries
sequences of 563 and 467 bp, respectively, which are identical to se-
quences directly flanking ppm2 and which are fused in pK19mobsacB-
Cg-ppm2. This vector carries the kanamycin resistance gene, as well
as sacB enabling two rounds of positive selection for integration of the
vector, and subsequent loss of the vector, respectively. The location of
the two primers used to confirm the chromosomal organization of ppm2
are indicated as arrows marked F2/R2. C, final confirmation of the
constructed strains via PCR analysis using chromosomal DNA from
C. glutamicum, of the ppm1 inactivation mutant (Cg::ppm1), and of the
ppm2 deletion mutant (Cgppm2). The outer lanes contain standards
with their sizes given in kb. With the primer pairs given as indicated,
the expected product sizes for analysis of the ppm1 locus were 377 and
350 bp, respectively, for strain Cg::ppm1 and 349 bp for C. glutamicum.
For analysis of the ppm2 locus, the expected product sizes were 1051 bp
for strain Cgppm2 and 2419 bp for C. glutamicum.
FIG. 2. Schematic diagram for the construction of the ppm
mutants derived from C. glutamicum. A, illustrated are the adja-
cent ppm1 and ppm2 genes and the strategy to disrupt ppm1 using the
inactivation vector pK18mob-Cg-ppm1-int. The inactivation vector car-
ries an internal 247-bp fragment of ppm1, given as a shaded box.
Homologous recombination and selection for kanamycin resistance re-
sults in strain Cg::ppm1 with disrupted ppm1 and without Ppm1 activ-
ity. The location of the three different primer pairs to confirm the
FIG. 3. Growth curve illustrating the effects on growth rate
after inactivation of Cg-ppm1 or deletion of Cg-ppm2. The effect
of inactivating Cg-ppm1 (C. glutamicum::ppm1) or deletion of Cg-ppm2
(C. glutamicumppm2), as compared with wild type C. glutamicum, is
shown over a 30-h period and measured at an optical density of 600 nm
spectrometrically. The effect of inactivating Cg-ppm1 (C. glu-
tamicum::ppm1) and complementation with either a plasmid encoded
Cg-ppm1 (C. glutamicum::ppm1 pCg-ppm1) or a plasmid encoded Mt-
ppm1/D2 (C. glutamicum::ppm1 pMt-ppm1/D2), as compared with wild
type C. glutamicum, is also shown.
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C. glutamicum, membrane fractions were incubated with and
without a range of exogenous commercially available polypre-
nol monophosphates. With the co-spotting of endogenous and
exogenously added PPM molecules, we were unequivocally able
to identify the corynebacterial PPM as an undecaprenol phos-
phate (C55) species (data not shown), similar in chain length to
those found in E. coli (45). Furthermore, we found, in complete
agreement with our previous studies, that the corynebacterial
synthase, Cg-Ppm1, showed a similar lack of specificity for
polyprenyl phosphates in relation to changes in the lipid moi-
ety, such as saturation of the -isoprenoid unit (35). However,
Cg-Ppm1 did show a small degree of specificity toward the
chain length of exogenous PPM molecules, with the optimal
enzymatic activity being observed with chain lengths  C35
(data not shown).
As expected the PPM synthase-specific enzymic activity from
the wild type strain was clearly evident (12.63 pmol/mg/min),
and C. glutamicum::ppm1 was found to possess no PPM
synthase activity (Fig. 5). The complemented mutant (C.
glutamicum::ppm1 pMt-ppm1/D2) was assayed for PPM syn-
thase activity, with our results showing a restoration of enzy-
matic activity to almost 50% of that observed in the wild type
strain (5.95 pmol/mg/min) (Fig. 5). The restoration of PPM
synthase activity in the complemented mutant, through the
use of a plasmid-encoded gene, further emphasizes that domain
2 of the M. tuberculosis ppm gene is catalytic, and, as expected,
Cg-ppm1 possesses the PPM synthase activity of the two or-
thologues identified in the C. glutamicum genome. In addition,
these results provide further evidence that corynebacteria rep-
resent a suitable model enabling functional studies using the
expression of mycobacterial genes.
In Vivo and in Vitro Characterization and Analysis of PIM
and Lipoglycan Biosynthesis in C. glutamicum—To date, we
are not aware of any studies comparing the nature of the in
vivo and in vitro synthesized PIM molecules in corynebacteria.
Therefore, we extracted the whole cell lipids, known to con-
tain PIM molecules (46, 47), from C. glutamicum and C. glu-
tamicum::ppm1 and analyzed these using two-dimensional
TLC. As revealed via TLC, both strains produced identical PIM
profiles (data not shown). In addition, the in vivo C. glutami-
cum lipids were analyzed by MALDI-MS (Fig. 6). In vivo,
C. glutamicum produces PI (C16/C18:1; m/z 835) and Ac1PIM2
(2C16/C18:1; m/z 1397) as the major species, as well as a minor
component characterized as Ac1PIM2 (C16/C18:1/C18; m/z 1425).
Moreover, the identification of these PIM species together with
the nature of the acyl groups is in complete agreement with
previous work (7).
With the identification of both lipoglycans and glycolipids in
the cell envelope of C. glutamicum, we reasoned that both
corynebacteria and mycobacteria should possess similar
biosynthetic pathways dedicated to the production of these
complex polysaccharides. The availability of amphomycin (a
lipopeptide antibiotic that specifically inhibits polyprenol-P-
requiring synthases, thus blocking the synthesis of C55-P-Man,
and the subsequent production of higher PIMs) meant we were
able to probe the initial in vitro steps involved in the production
of PIMs in C. glutamicum. Both C. glutamicum and
C. glutamicum::ppm1 were examined for GDP-Man-dependent
mannosyltransferase activities associated with PIM biosynthe-
FIG. 4. SDS-PAGE of crude cellular extracts illustrating over-
expression of Mt-ppm1/D2 in C. glutamicum. Crude cellular ex-
tracts were prepared, and in each case 10 g was subjected to SDS-
PAGE (12%) and stained with Coomassie Blue. Lane 1, C. glutamicum;
lane 2, C. glutamicum::ppm1, empty pXMJ19; lane 3, C. glutamicum::
ppm1 pMt-ppm1/D2. The arrow indicates the extra band resulting from
the expression of pXMJ19-Mt-ppm1/D2. Molecular masses of reference
proteins are indicated.
FIG. 5. Thin layer chromatogram of labeled endogenous poly-
prenol monophosphates using GDP-[14C]Man and membrane
extracts from C. glutamicum, C. glutamicum::ppm1, and C. glu-
tamicum::ppm1 pMt-ppm1/D2. Membrane fractions were incubated
with GDP-[14C]Man in a total volume of 50 l for 30 min and synthe-
sized products isolated after mild base treatment. Aliquots (10%) were
taken for scintillation counting and TLC/autoradiography using CHCl3/
CH3OH/NH4OH/H2O (65:25:0.4:3.6, v/v/v/v). Lane 1, C. glutamicum;
lane 2, C. glutamicum::ppm1; lane 3, C. glutamicum::ppm1 pMt-ppm1/
D2. Assays were performed in triplicate using freshly prepared mem-
branes, with the thin layer chromatogram representative of a number of
samples from independent experiments.
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sis using an in vitro cell-free assay system. Assays were per-
formed with freshly prepared membranes from both strains.
Using thin layer chromatography/autoradiography, we ob-
served one species of in vitro synthesized PIM molecules (Fig.
7). Indeed, using large scale assays with unlabeled GDP-Man
and C. glutamicum membrane preparations, we were able to
extract this species and characterize it using MALDI-MS (Fig.
6, inset). As expected both strains produced identical products,
which were characterized as Ac1PIM2 (C16/C18/C18:1; m/z 1425)
(Fig. 6, inset). Interestingly, the in vitro C. glutamicum mem-
brane extracts synthesize only Ac1PIM2 (m/z 1425), which is
the minor PIM species synthesized by C. glutamicum in vivo.
The subsequent synthesis of higher PIMs (Ac1PIM3, etc.) and
linear LM (31) in C. glutamicum was completely abrogated
because of inhibition of the required C55-P-Man sugar donor by
amphomycin, which was also the case, as expected, when we
analyzed C. glutamicum::ppm1 (data not shown). These results
mirror previous studies on the use of amphomycin and the
subsequent synthesis of linear LM (31).
Mycobacterial LAM is an important factor in tuberculosis
immunopathogenesis, and is a major component in the cell
architecture of the tubercle bacilli, along side the other biosyn-
thetically related lipoglycans such as lipomannan and glycolip-
ids including PIMs. These complex lipoglycans are composed of
many different carbohydrate residues, with the mannan do-
main typically composed of 6-Manp, 2,6-Manp, and t-Manp
residues. The purified lipoglycans from C. glutamicum were
examined via glycosidic linkage analysis, and the same resi-
dues were identified (data not shown). Moreover, through al-
kaline hydrolysis of the intact lipoglycan, we were able to
distinguish C16, C18:1, and C18 fatty acids in the ratio 1:0.6:
0.1. Finally, the lipoglycan was hydrolyzed in strong acid con-
ditions and the resulting hydrolysates analyzed using capillary
electrophoresis coupled to laser induced florescence. This dem-
onstrated that the lipoglycan was composed exclusively of
Manp residues (data not shown). Altogether this pointed to the
presence of a LM-like lipoglycan within the cell envelope of
C. glutamicum, and was in complete agreement with the pre-
vious work of Puech et al. (7). In this study we have previously
demonstrated, through the indirect use of amphomycin and the
direct use C. glutamicum::ppm1, that the formation of higher
PIMs and linear LM is dependent on the transfer of mannose
from GDP-Man to undecaprenol phosphate, which then acts as
the sugar donor for the growing lipoglycan (31, 35). With this in
mind, we examined whether in vivo lipoglycan biosynthesis
was affected by the inactivation of Cg-ppm1. Crude lipoglycan
extractions were prepared from C. glutamicum, C. glutami-
cum::ppm1, and C. glutamicum::ppm1 pMt-ppm1/D2. The re-
FIG. 8. SDS-PAGE of lipoglycans extracted from C. glutami-
cum, C. glutamicum::ppm1, and C. glutamicum::ppm1 pMt-
ppm1/D2. Lipoglycans were extracted from equivalent biomass using
the hot phenol/water method and subjected to SDS-PAGE (15%) and
stained with periodic acid and silver nitrate. Lane 1, sample extracted
from C. glutamicum; lane 2, sample extracted from C. glutamicum::
ppm1; lane 3, sample extracted from C. glutamicum::ppm1 pMt-ppm1/
D2; lane 4, 15 g of purified M. tuberculosis H37Rv ManLAM.
FIG. 6. Characterization of in vivo and in vitro synthesized
PI/PIMs. Figure shows negative ion mode MALDI-MS analysis of total
lipidic extract from C. glutamicum. Inset, negative ion mode
MALDI-MS analysis of the in vitro synthesized PIMs from C. glutami-
cum. The peaks observed are m/z 835, PI with C16/C18:1 fatty acyl
groups; m/z 1397, Ac1PIM2 with 2C16/C18:1 fatty acyl groups; and m/z
1425, Ac1PIM2 with C16/C18:1/C18 fatty acyl groups. Major peaks, iden-
tified by asterisks with m/z values of 770, 949, 991, and 1013, respec-
tively, were not attributable to any PIM species and as such may
represent unidentified lipid species and/or plasticizer.
FIG. 7. Thin layer chromatogram of labeled endogenous PPMs
and PIMs using GDP-[14C]Man and membrane extracts from
C. glutamicum and C. glutamicum::ppm1. Membrane fractions
were incubated with GDP-[14C]Man in a total volume of 50 l for 30 min
and synthesized products isolated after aqueous treatment, enabling
the recovery of the base-labile PIMs. Aliquots (10%) were taken for
scintillation counting and TLC/autoradiography using CHCl3/CH3OH/
NH4OH/H2O (65:25:0.4:3.6, v/v/v/v). Lane 1, in vitro synthesized PPMs
and PIMs from C. glutamicum; lane 2, in vitro synthesized PIMs from
C. glutamicum, demonstrating the inhibition of PPM synthesis via the
addition of amphomycin (5 g); lanes 3 and 4, in vitro synthesized PIMs
from C. glutamicum::ppm1, showing the inability of this mutant to
synthesize PPMs with and without the presence of amphomycin,
respectively.
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sults observed were fascinating; the inactivated mutant had
lost all ability to synthesize lipoglycans (Fig. 8), which sug-
gests that the amelioration of growth rate observed in the
C. glutamicum::ppm1 mutant is linked to the production of a
full complement of lipoglycans, presumably enabling the bac-
teria to form a suitable corynebacterial cell envelope. Because
we had established that the plasmid-encoded Mt-ppm/D2 was
functional when introduced to C. glutamicum::ppm1, we
assumed that, when we analyzed the complemented mutant
(C. glutamicum::ppm1 pMt-ppm1/D2), we would observe resto-
ration of lipoglycan production. Indeed, when the crude lipo-
glycans were visualized using SDS-PAGE followed by silver
nitrate-periodic acid staining, there were no observable differ-
ences (Fig. 8), suggesting a key conserved role for this synthase
in both mycobacteria and corynebacteria.
DISCUSSION
Mycobacterial LAM is now well accepted as an important
immunomodulatory molecule, and plays a significant role in
the pathogenesis of tuberculosis. Indeed, a recent study has
defined the precise role ManLAM plays in the molecular basis
of mycobacterially induced phagosome maturation arrest (48).
Moreover, a recent review on mycobacterial LAM suggests that
LAM will continue to evolve and emerge as an important vir-
ulence factor for tuberculosis (11). Given the importance of this
lipoglycan, it appears perplexing that we know very little about
the biosynthetic pathways involved in its production and reg-
ulation. A number of lipoglycans structurally akin to mycobac-
terial LAM have been characterized from related Actinomyce-
tales, providing a network of structural information relating to
conserved domains within these macromolecules. It seems that
the MPI anchor and mannan domain is structurally conserved
between genera, whereas the greatest variation is found within
the arabinan domain of these LAM-like molecules (11). With
the general degree of conservation in both the MPI anchor and
mannan region, we chose to undertake a biochemical and mo-
lecular study aimed at identifying key enzymes common to both
mycobacterial and corynebacterial lipoglycan biosynthesis.
Previous studies have reported the presence of lipoglycans
within the corynebacterial cell envelope (7, 9), and our present
study has shown that both PIMs and an LM-like molecule exist
in C. glutamicum and C. pseudotuberculosis.4 These facts sup-
port the notion that there are highly conserved biosynthetic
pathways within the Actinomycetales family, dedicated to the
production of these lipoglycans. The precise in vivo role and
function of these molecules within the corynebacteria is cur-
rently unknown. However, because they are generally non-
pathogenic, one may presume they play a crucial role in cell
envelope architecture, a fact illustrated by the altered growth
rate of the Cg-ppm1 inactivated mutant described in this study.
Further evidence for this hypothesis is provided by the findings
of Puech et al. (7), who noted that the corynebacterial cell
envelope does not contain enough mycolic acids to cover the
entire cell surface (7). They suggested that non-covalently as-
sociated lipids may compensate for the lack of mycolic acids,
and enable the production of a satisfactory hydrophobic cell
envelope (7). From our findings it would appear that glycolipids
and lipoglycans, also non-covalently associated macromole-
cules, play a role in determining overall cell architecture, and
could supplement the lipids present in the cell envelope.
Detailed genomic analysis of C. glutamicum revealed ortho-
logues of Mt-ppm1 (Rv2051c), which were termed Cg-ppm2
(transmembrane domain, orthologue of Mt-ppm1/D1) and Cg-
ppm1 (catalytic domain, orthologue of Mt-ppm1/D2). This level
of organization is in contrast to that found in M. tuberculosis
H37Rv, where Mt-ppm1 has been postulated to be the result of
a recent genetic fusion, resulting in a single bi-functional gene,
where Mt-ppm1/D1 is the transmembrane domain and Mt-
ppm1/D2 possesses catalytic activity (35). The genetic arrange-
ment of the corynebacterial orthologues is more reminiscent of
the ppm genes found in other mycobacterial strains such as
M. avium, M. smegmatis, and M. leprae, as shown in Fig.1A.
The present study highlights the overall importance of the
Ppm synthase in lipoglycan biosynthesis. We have established
that, when C. glutamicum lacks a functional copy of Cg-ppm1,
it is unable to produce any mature lipoglycans, but can still
produce PIMs. The importance of these findings has wider
implications for several reasons. First, a number of reports
have identified several mannosyltransferases, termed pimA,
pimB, and pimC within mycobacterial genomes, which have
been shown to be involved in PIM1–3 biosynthesis (32–34).
pimA has been shown to be essential for mycobacterial growth,
as it initiates lipoglycan biosynthesis through the production of
PIM1. In contrast, both pimB
5 and pimC have been shown to be
nonessential, such that disruption of the open reading frames
provides no obvious phenotype, i.e. LM/LAM-negative. Because
disruption provided no obvious phenotype, it suggests that
there are other redundant enzymes and pathways, which are
able to compensate for such enzyme(s). A key goal of mycobac-
terial research is the generation of truncated variants of both
LM and LAM. The recent definition of the Ppm1 synthase
enzyme and its involvement in the extension of PIM precur-
sors, leading to the generation of LM, has highlighted the
enzyme as a worthy candidate for gene disruption leading to
LM/LAM-negative mutants in mycobacteria. However, because
of the intrinsic complications involved in the genetic manipu-
lation of mycobacteria, such disruptions are likely to prove
more fruitful through the initial exploitation of more tractable
genetic models, such as C. glutamicum. Furthermore, we have
found that restoration of growth rate and lipoglycan production
can be observed in the C. glutamicum::ppm1 mutant by func-
tional complementation with a plasmid-encoded copy of
Mt-ppm1/D2. This finding highlights the utilization of heterol-
ogous expression of mycobacterial proteins within corynebac-
teria to resolve in vivo and in vitro roles of key enzymes (49,
50). As opposed to studies with pimB and pimC, further
genomic and biochemical analysis established no compensatory
mechanism(s) within the corynebacterial genomes, when the
Cg-ppm1 gene was inactivated.
In summary, our current findings suggest that the inactiva-
tion of Mt-ppm1/D2 would be nonessential for M. tuberculosis,
and provide tubercle bacilli lacking both LM and LAM. The
generated mutants could then be used in detailed immunolog-
ical studies aimed at defining the exact in vivo functions LM
and LAM in tuberculosis pathogenesis. Moreover, if their in
vivo roles are shown to echo the myriad of established in vitro
functions, then ultimately this may lead to the development of
novel agents that target this enzyme system, and as such a
potential new breed of anti-mycobacterial drugs.
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